Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.54 |
| ▸ | HTR3B | O95264 | 3/20 | 0.54 |
| ▸ | HTR3A | P46098 | 3/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570950 | 0.82 | GRIN2B (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3384448 | 0.79 | PDE10A (0.48) | HTR3A | |
| SCHEMBL3574947 | 0.77 | HRH3 (0.43) | — | |
| SCHEMBL3574996 | 0.77 | CHRNB2 (0.56) | MEN1KMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL3581626 | 0.76 | HRH3 (0.42) | — | |
| SCHEMBL3389755 | 0.75 | GRIN2D (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3384524 | 0.75 | HRH3 (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3572278 | 0.74 | TRPV1 (0.36) | HTR3A | |
| SCHEMBL7382691 | 0.74 | HTR3E (0.70) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL20689451 | 0.74 | HTR3E (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | claimed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | claimed |
| EP-1987031-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NeuroSearch A/S (DK) | 2008-11-05 | — | — | EP | claimed |
| WO-2007090888-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | claimed |
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | disclosed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1987031-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NeuroSearch A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007090888-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | CHRNA3, CHRNA10, CHRNB3 | HTR3E 77/4885HTR3B 47/4885HTR3A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.